Technology

Technology

iMOST Platform: Making Instant Mobile Health Test a Reality

There is a good reason that traditional clinical lab testing requires complex machines, professional operation, and laboratory settings (hence they are inconvenient, time-consuming, and expensive). It is needed for test accuracy, since traditional lab-tests employ a “precision paradigm” that requires machines, processes, and operations precise to achieve test accuracy.

To transform clinical lab tests into an accurate mobile personal test, Essenlix abandoned the “precision paradigm”, and instead developed a fundamentally new paradigm: the “intelligent fault tolerant paradigm”, together with other innovations, that are capable to deliver clinical lab-quality test results using a simple device, even when a sample, device, process, and operation are imperfect.

A second obstacle for achieving instant mobile testing is that traditional POC tests require many different instruments and sample holder formats for different tests. iMOST™ is designed to be versatile, using one unique sample holder platform and one instrument to test different sample types (blood, saliva, urine, swab, sputum, breath, mucus, tissue, etc.), different assays (immunoassay, colorimetric assay, cytology and pathology, nucleic acid assay, etc.) and different biomarkers (cells, proteins, nucleic acids, and small molecules).

Other innovations in iMOST are designed to make iMOST fast (in minutes), tiny sample volume (5-10 uL), easy-to-use, real-time test monitored and calibrated, mobile connected, reliable, low maintenance / service, and low operation cost. Furthermore, the intelligent fault tolerant paradigm enables iMOST readers to be simple in structure and small in size, and to be produced in millions at a low cost.

iMOST™ (Instant Mobile Self-Test), first of the type, is based on outside-the-box thinking and a fundamentally different paradigm. The new paradigm is being realized through uniquely implementing nanotechnology, advance imaging, Nano-Enabled Artificial intelligence/Machine-learning (NEAM) and new bio/chemical processes into diagnostic testing.